Summit Therapeutics (NASDAQ:SMMT) just reported results for the second quarter of 2024.
- Summit Therapeutics reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -6 cents.
- The company did not report any revenue for the quarter.